Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease

KP Bhat, H Ümit Kaniskan, J Jin… - Nature Reviews Drug …, 2021 - nature.com
Protein lysine methylation is a crucial post-translational modification that regulates the
functions of both histone and non-histone proteins. Deregulation of the enzymes or 'writers' …

DNA repair pathways in cancer therapy and resistance

L Li, Y Guan, X Chen, J Yang, Y Cheng - Frontiers in pharmacology, 2021 - frontiersin.org
DNA repair pathways are triggered to maintain genetic stability and integrity when
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents. The …

Dynamic de novo heterochromatin assembly and disassembly at replication forks ensures fork stability

V Gaggioli, CSY Lo, N Reverón-Gómez… - Nature cell …, 2023 - nature.com
Chromatin is dynamically reorganized when DNA replication forks are challenged. However,
the process of epigenetic reorganization and its implication for fork stability is poorly …

[HTML][HTML] Mechanisms of chemotherapy resistance in ovarian cancer

M Ortiz, E Wabel, K Mitchell, S Horibata - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for
ovarian cancer has been the same for the past two decades, a combination treatment of …

Understanding and targeting resistance mechanisms in cancer

ZN Lei, Q Tian, QX Teng, JND Wurpel, L Zeng… - MedComm, 2023 - Wiley Online Library
Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer

M Chiappa, F Guffanti, F Bertoni, I Colombo… - Drug Resistance …, 2021 - Elsevier
Ovarian cancer is the fifth cause of cancer-related deaths in women with high grade serous
carcinoma (HGSOC) representing the most common histological subtype. Approximately …

Ovarian cancer: epigenetics, drug resistance, and progression

W Xie, H Sun, X Li, F Lin, Z Wang, X Wang - Cancer cell international, 2021 - Springer
Ovarian cancer (OC) is one of the most common malignant tumors in women. OC is
associated with the activation of oncogenes, the inactivation of tumor suppressor genes, and …

EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms

A Nachiyappan, N Gupta, R Taneja - The FEBS Journal, 2022 - Wiley Online Library
Metastasis, therapy failure and tumour recurrence are major clinical challenges in cancer.
The interplay between tumour‐initiating cells (TICs) and epithelial–mesenchymal transition …

PARP inhibitor resistance mechanisms and implications for post-progression combination therapies

EK Lee, UA Matulonis - Cancers, 2020 - mdpi.com
The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use
from the recurrence setting to the frontline setting. In parallel, the population developing …

The SETDB1–TRIM28 complex suppresses antitumor immunity

J Lin, D Guo, H Liu, W Zhou, C Wang, I Müller… - Cancer immunology …, 2021 - AACR
The tumor immune microenvironment is influenced by the epigenetic landscape of the
tumor. Here, we have identified the SETDB1–TRIM28 complex as a critical suppressor of …